Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Mesothelin CAR-T in Mesothelin-positive Advanced Solid Tumors
NCT05783089Phase 1Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label trial of UCLM802 in mesothelioma, pancreatic cancer (PC), biliary tract cancer (BTC) and 8 more, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
UCLM802
03
Conditions
mesotheliomapancreatic cancer (PC)biliary tract cancer (BTC)lung cancerovarian cancer
Beyond the preview
Go deeper on NCT05783089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05783089.